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Abstract 
Background: Placenta accreta is a rare obstetric condition but can lead to life‑threatening complications that was 
mainly diagnosed in the third trimester. We present a case of acute trophoblastic pulmonary embolism (PE) during 
conservative treatment of placenta accreta.
Case presentation: A 24‑year‑old patient who delivered vaginally at 40+4 weeks gestation. The placenta was 
retained despite the use of oxytocics and attempts of manual removal. Conservative management including uterine 
arteria embolism, hysteroscopic resection and mifepristone was used but failed and finally the patient died from 
acute trophoblastic PE and allergic shock when infusing povidone‑iodine into her uterine cavity.
Conclusion: Although conservative treatment of placenta accreta can retain reproductive potential and trophoblas‑
tic PE is rare, clinicians should consider hysterectomy when conservative treatment failed and infusion of povidone‑
iodine or other liquid into the cavity should be prohibited.
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Background
Placenta accreta indicates deep attachment of the pla-
centa to myometrium due to the absence of decidua 
basalis [1]. The optimal management of this condition 
remains controversial. Although hysterectomy is a choice 
for retained placenta, leaving the placenta in  situ with 
conservative treatment such as uterine arteria embolism, 
mifepristone, methotrexate and hysteroscopic resection 
can also be undertaken when there is no hemorrhage 
and the patient want to preserve her fertility. Conserva-
tive management also has some risk such as hemorrhage, 
infection, failure and subsequent hysterectomy, and even 
death [2].
We present a unique case of death caused by acute 
trophoblastic PE and anaphylactic shock during 
conservative treatment of placenta accreta. To our knowl-
edge, this is the first report about trophoblastic PE during 
conservative management of placenta accreta.
Case presentation
A woman with a history of one spontaneous miscarriage 
of 7-week gestation without curettage or other treatment 
had a vaginal delivery at 40+4 weeks gestation. The pla-
centa was retained in the cavity despite the use of oxy-
tocics. Manual removal of the placenta was attempted, 
but unsuccessful. Emergency  ultrasound scan revealed 
placenta tissue measuring 165 × 130 × 94 mm3 without 
a clear boundary with myometrium. Magnetic resonance 
imaging (MRI) confirmed placenta accreta the next day 
(Fig. 1). Her pre-delivery hemoglobin concentration was 
11.9 g/dL and the estimated blood loss was 200 mL with-
out active hemorrhage. She wanted to keep her uterus 
and declined hysterectomy, so uterine arterial embolism 
was performed in case of massive hemorrhage. After 
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embolization, her general condition was fine except mild 
pelvic pain. Prophylactic intravenous injections of Cefa-
zolin Sodium Pentahydrate 1.0  g and Ornidazole  0.5  g, 
12 hourly were used to decrease the chance of infection. 
3 days later her body temperature raised to 38.3 °C, labo-
ratory result on C reactive protein was >200  mg/L and 
white blood cell count was 18.5 × 109/L. Escherichia coli 
was isolated from vagina secretion. Conservative treat-
ment needed to be abandoned but she still declined hys-
terectomy. Cefazolin Sodium Pentahydrate was changed 
to Cefoperazone-Sulbactam 3  g, 12 hourly according to 
the drug-sensitive  test. Her general condition became 
better and  she was transferred to gynecology. To accel-
erate the placenta elimination, hysteroscopic resection 
was undertaken 9 days after her delivery. Placenta could 
be seen everywhere in the cavity from the hysteroscope. 
The surgery had to terminated 90  min later to avoid 
water intoxication. About 6 × 6×1 cm3 of placenta was 
resected. Mifepristone was used 25  mg orally daily to 
promote necrosis of trophoblastic as her serum β-hCG 
was still 2608 mIU/ml. The next day after hysteroscopy 
her body temperature  raised to 40.3  °C. Blood culture 
was negative but Escherichia coli could still be found in 
vagina secretion. Antibiotics were changed to Amikacin 
0.6 g q12 h and Cefoxitin 2.0 g q8 h according to drug-
sensitive  test. Purulent secretion and necrotic tissue 
can be seen in the cervix and cavity during gynecologi-
cal examination. Povidone-iodine was infused into her 
cavity to wash out the purulent secretion and necrotic 
tissue with a double cavity flexible pip with her permis-
sion. During this procedure, the second time the patient 
immediately experienced dyspnea and lost consciousness 
soon after about 15 mL povidone-iodine was infused into 
her cavity. The clinical picture suggested acute respira-
tory distress syndrome. Cardiopulmonary resuscitation 
was performed immediately. However, despite all efforts, 
the patient died. Written consent was obtained from her 
relatives and autopsy was performed to investigate the 
underlying pathological condition. Autopsy revealed that 
trophoblastic PE (Fig. 2) and anaphylactic shock (Fig. 3) 
were the causes of her death.
Discussion
Commonly risk factors for placenta accreta are previous 
cesarean section, dilatation and curettage, placenta  pre-
via, previous uterine injury or surgery [3]. As the cesar-
ean section rate and artificial abortion rates are rising, 
the placenta accreta rate is also increasing [4], especially 
in China. In some part of mainland China, the cesarean 
section rate is as much as 54.9 %, the highest in the world 
[5]. In contrast to many reports, our patient had no risk 
factor mentioned above.
Ultrasound and MRI have been described to diagnose 
placenta accreta in literature. However, prenatal diagno-
sis of placenta accreta remains a challenge. Most of pla-
centa accreta was diagnosed in the third  stage  of  labor 
[6]. One prospective population-based study of women 
diagnosed with placenta accreta found that only less 
than 50 % (66/133) were suspected antenatally. Antena-
tally diagnosis of placenta accreta reduced the ratio of 
Fig. 1 MRI demonstrates segment of placenta extending outside of 
the visible myometrium
Fig. 2 Histopathological picture showing that trophoblastic emboli 
can be found in the pulmonary interstitial vessels
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hemorrhage and blood transfusion with statistical  sig-
nificance. So antenatally diagnosis is very important for 
placenta accreta [7]. In our case, prenatal ultrasound also 
did not diagnose the placenta accreta.
Placenta accreta morbidity is mainly caused by hem-
orrhage, especially when surgical attempts are used to 
remove the placenta, which can cause intraoperative and 
postoperative maternal morbidity, large-volume blood 
transfusions, ureteral damage, intraabdominal infection 
[2]. So surgical attempts to remove placenta should be 
avoided when placenta accreta is suspected. The options 
for managing placenta accreta include hysterectomy and 
conservative treatment. If the placenta accreta was diag-
nosed before delivery or during cesarean section, cesar-
ean hysterectomy is generally considered the standard 
treatment for placenta accreta. Subsequent hysterectomy 
after vaginal delivery is also appropriate when massive 
hemorrhage is threatening life. Conservative treatment 
may be applied for some women who want to keep their 
uterus when there is no hemorrhage.
There is no standard conservative treatment option 
for placenta accreta. Conservative treatment includes 
uterine artery embolization, methotrexate, mifepris-
tone and hysteroscopic resection. Uterine artery cath-
eterization can reduce risk of massive hemorrhage in 
the management of placenta accreta [8]. Methotrexate 
has been used to promote the necrosis and resorption of 
placenta. However, methotrexate has some serious side 
effects, women unable to breastfeed and a maternal death 
related to the use of methotrexate has been reported 
[2]. Royal College of Obstetricians and Gynaecologists 
noted that methotrexate has little benefit in enhancing 
placental resorption [9]. Mifepristone has been success-
fully used in placenta accreta without any complication 
[10]. Leaving the placenta in situ after delivery can delay 
placental expulsion or resorption for weeks or even 
months. Resection of persistent retained placenta tissue 
by hysteroscopy can shorten this period and reduce the 
risk for infection and bleeding [11]. One large series on 
the conservative treatment of placenta accreta includes 
uterotonic drugs (oxytocin or sulprostone or both), pro-
phylactic antibiotic therapy, methotrexate, pelvic arterial 
embolization. The success rate of this study was 78.5  % 
(131/167) and the remaining 36 women had hysterec-
tomy [2]. In our case, although three conservative treat-
ments were applied to her, the serum β-hCG was still 
2890 mIU/mL before death. Her body temperature and 
laboratory result suggested she got an infection. Those 
indicate that conservative treatments were not appropri-
ate for her and hysterectomy should be applied immedi-
ately but she declined.
PE is defined as embolisation to the pulmonary circu-
lation by thrombus, adipocytes, amniotic fluid, tumor, 
bacteria, or gas, but trophoblastic tissue is very rare. 
Unlike other kind of embolus, the presence of tropho-
blastic tissue in the maternal circulation is not consid-
ered abnormal [12]. Between 30 and 80  % of obstetric 
patients have trophoblastic cells in their peripheral cir-
culation. However, the quantity of trophoblastic tissue 
found in pulmonary vessels indicates that trophoblastic 
PE led to maternal death. The diagnosis of trophoblas-
tic PE is based on both clinical information and patho-
logical outcomes [13]. Ikarashi et  al. [14] identified two 
histopathological patterns of trophoblastic PE: one com-
posed of intact trophoblastic cells similar to those seen in 
chorionic villi and identified easily by H&E staining; the 
other consisted of amorphous and fragmented tropho-
blastic cells that were more difficult to identify by routine 
staining.
Trophoblastic PE was first described by Schmorlin 
1893 in a postmortem study of eclamptic patients [15]. 
Most of trophoblastic PE happens in gestational tropho-
blastic disease, during cesarean section and curettage. 
Garner et al. [16] report on trophoblastic PE in a young 
woman following abdominal hysterectomy for inva-
sive gestational trophoblastic disease. Fortunately, she 
got complete recovery after 72  h with the treatment of 
supportive measures. Tews et  al. [13] report on sudden 
death in a young woman following cesarean section and 
histological investigation revealed trophoblastic cells 
within the lumen of small-sized pulmonary vessels and 
thought that microscopic injuries during decompres-
sion punctures might have favored the deportation of 
trophoblastic tissue into the maternal circulation. Seiryu 
et al. [17] report on trophoblastic PE in a young woman 
during the curettage procedures of 7-week gestation and 
thought that the trophoblastic PE was caused by direct 
Fig. 3 Histopathological picture showing that a lot of eosinophils 
can be found in pulmonary interstitial vessels
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access of trophoblastic tissues to the uterine veins drain-
ing the maternal intervillous space during the curettage 
procedures.
To our knowledge, this is the first case of trophoblas-
tic PE to occur during conservative treatment of placenta 
accreta. The pathogenesis of emboli is far more com-
plex than mechanical obstruction of vascular, especially 
nonthrombotic emboli. Nonthrombotic emboli such as 
trophoblastic cells may also lead to a severe inflammatory 
reaction [18]. In our case, anaphylactic shock also accom-
panied the trophoblastic PE.
Povidone-iodine is commonly used in infectious 
wound. We infused povidone-iodine into her cavity with 
the purpose of washing out necrotic tissue and purulent 
secretion to reduce infection. There was no active hem-
orrhage so we did not predict that povidone-iodine or 
some other things could get into her circulation. May be 
the reason for trophoblastic PE was that as three con-
servative treatments had been applied to her, the retained 
placenta is necrotic and loosely adhered to the myome-
trium. The sudden introduction of povidone-iodine may 
have detached part of the placenta and exposing a blood 
vessel; the trophoblastic cells entered the blood circula-
tory  system and the trophoblastic PE happened. There-
fore, infusion of povidone-iodine or some other liquid 
to the cavity during conservative treatment of placenta 
accreta should be avoided.
Conclusion
We present a unique case of acute trophoblastic PE 
during conservative treatment of placenta accreta in a 
24-year-old female. Careful evaluation of this rare com-
plication and painful lesson may provide us some expe-
rience in the treatment of placenta accreta. This case 
reminds us that hysterectomy should be employed when 
conservative treatment of placenta accreta fails to avoid 
severe complications. Infusion of povidone-iodine or 
other liquid to the uterine cavity during conservative 
treatment of placenta accreta should be avoided.
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